Zacks Investment Research
24 Nov 2025, 15:41 UTC · 47w ago
Verdict
Headline takes no side. We score CAH +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The Zacks Consensus Estimate for Aurinia Pharmaceuticals' (AUPH) full-year earnings has increased by 20.3% over the past quarter.
More positive than 80% of claims this week
Aurinia Pharmaceuticals (AUPH) currently holds a Zacks Rank of #2 (Buy).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 68% of claims this week
Cardinal Health (CAH) has a Zacks Rank of #2 (Buy) and has seen its consensus EPS estimate for the current year increase by 4.2% over three months.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), increasing consensus EPS estimates, and has outperformed its sector with a 77.1% return.
More positive than 99% of ticker scores this week
The company has a Zacks Rank of #2 (Buy), positive earnings estimate revisions, and is significantly outperforming its sector peers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
26m ago
+22.9%
Price agrees with the score
$257.46 vs $209.48 close before publication (Nov 21) · not market-adjusted
CAH chart →
